Iron is an essential micronutrient for a myriad of physiological processes in the body beyond
erythropoiesis. Iron deficiency (ID) is a common comorbidity in patients with heart failure …

For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …

Introduction This integrated phase 3 analysis examined efficacy and cardiovascular safety
for roxadustat vs erythropoiesis-stimulating agents (ESAs) in dialysis-dependent patients …

Roxadustat is a recently approved hypoxia-inducible factor prolyl hydroxylase inhibitor that
has demonstrated favorable safety and efficacy in the treatment of renal anemia. Recent …

Background: Five types of HIF-PHIs have been authorized for anemia treatment in CKD
patients in China and Japan. These are enarodustat, roxadustat, daprodustat, vadadustat …

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a new class of oral
medicines being developed for the treatment of anemia in chronic kidney disease (CKD) …

Hypoxia inducible factors (HIFs) and their regulatory hydroxylases the prolyl hydroxylase
domain enzymes (PHDs) are the key mediators of the cellular response to hypoxia. HIFs are …

Erythropoiesis is a complex process driving the production of red blood cells. During
homeostasis, adult erythropoiesis takes place in the bone marrow and is tightly controlled by …

Repairing multiphasic defects is cumbersome. This study presents new soft and hard
scaffold designs aimed at facilitating the regeneration of multiphasic defects by enhancing …

The pharmacokinetics of roxadustat are well characterized, with an apparent volume of
distribution after oral administration of 22–57 L, apparent clearance of 1.2–2.65 L/h, and …